- Conditions
- Healthy
- Interventions
- IVX-A12, Placebo
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- CP-751,871, paclitaxel, carboplatin, erlotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more
- Conditions
- Cancer, Cancer, Treatment-Related, Medication Adherence, Communication, Tyrosine Kinase Inhibitor
- Interventions
- Oncotool Intervention (symptom reporting + TKI education), Oncotool Control (health information)
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Cardiac Rehabilitation, Motivational Interviewing
- Interventions
- Motivational Interviewing
- Behavioral
- Lead sponsor
- Auburn University
- Other
- Eligibility
- Not listed
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Ileostomy, Colostomy
- Interventions
- Coloplast Test A, Coloplast Test B, Subjects own product
- Device
- Lead sponsor
- Coloplast A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Saint Paul, Minnesota • Cleveland, Ohio
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3025876, Placebo, Liraglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Orange, California • Miami, Florida + 1 more
- Conditions
- Healthy
- Interventions
- Methylphenidate, Triazolam, Project: EVO, Placebo
- Drug · Other
- Lead sponsor
- Akili Interactive Labs, Inc.
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Smoking Cessation, Obesity
- Interventions
- Self-Regulation strategies + large changes (SR), Healthy Lifestyle Education (LE), Smoking Cessation Treatment
- Behavioral · Other
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 141
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 120 more
- Conditions
- Treatment Adherence
- Interventions
- Phone Coaching, Text Message Coaching, ACT Guide
- Behavioral
- Lead sponsor
- Utah State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Logan, Utah
- Conditions
- HIV, Gonorrhea, Chlamydia
- Interventions
- Keep It Up!, HIV Knowledge Control
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 29 Years · Male only
- Enrollment
- 901 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York
- Conditions
- Facial Injuries
- Interventions
- Fat Grafting, General Anesthesia, Coleman Cannulas, Tefla non-adherent gauze pad
- Procedure · Drug · Device + 1 more
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Multiple Myeloma, Large-cell Lymphoma
- Interventions
- Selinexor
- Drug
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Carotid Artery Calcification, Carotid Artery Diseases
- Interventions
- Carotid Intravascular Lithotripsy (IVL)
- Device
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more
- Conditions
- Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
- Interventions
- Standard of Care, Revita, Relese, Cogenex, Enverse
- Other
- Lead sponsor
- StimLabs
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • Tulsa, Oklahoma • Jefferson Hills, Pennsylvania + 2 more
- Conditions
- Hepatitis C
- Interventions
- IMO-2125, Saline placebo
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Marietta, Georgia • Novi, Michigan + 3 more
- Conditions
- Obesity
- Interventions
- AMG 598, Placebo, Liraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more
- Conditions
- Mental Health Services, Mobile Technologies, Technology Development
- Interventions
- SMARTwrap
- Behavioral
- Lead sponsor
- 3-C Institute for Social Development
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Bronchiectasis, Bronchiectasis With Acute Exacerbation
- Interventions
- High Frequency Chest Wall Oscillation, Oscillating Positive Expiratory Pressure (OPEP)
- Device
- Lead sponsor
- Hill-Rom
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York • Nashville, Tennessee • Tyler, Texas
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
- Interventions
- Durvalumab, Tremelimumab, Poly-ICLC
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more